in Supplementary information S2 (box)). The United States was the single largest country conducting clinical trials, with 58,980 trials (30%). The absolute increase was greatest for the Asian region (489%) and the Latin American/Caribbean region (112%); the smallest increase occurred in the North American region (9%) (FIG. 1b) .
Clinical trials were also classified by the economic development status of the countries involved. Over the 2005-2012 period overall, 77% of trials were conducted in the group of 24 high-income OECD (Organisation for Economic Co-operation and Development) countries, including the United States (FIG. 1c; see Table 2 in Supplementary information S2 (box)). From 2005, absolute growth was highest among lower-middle-income (594%) and low-income (247%) countries (FIG. 1d) . Meanwhile, high-income non-OECD and high-income OECD countries excluding the United States had increases of 36% and 59%, respectively. There was an 11% increase in the absolute number of trials conducted in the United States, but the proportion of trials globally decreased from 35% in 2005 to 24% in 2012. The proportion of registered trials globally increased in low-income (2% to 5%) and lower-middle-income (4% to 16%) countries (P < 0.0001).
The highest average clinical trial densities over the 2005-2012 period were in North America, Europe and Oceania, as well as in high-income OECD and non-OECD countries. The 48 low-income countries averaged 0.3 trials per 10 6 people, or one clinical trial for every 3 million people. Denmark had the highest average trial density (107 trials per 10 6 people), and other high-density countries included Estonia, the Netherlands, Israel and Finland (see Table 5 in Supplementary information S2 (box)).
The largest average annual growth rate from 2005 to 2012 occurred in Asian (30%) and Latin American/Caribbean (12%) regions; other geographic regions had growth rates that were lower than the global average (8%; see Table 2 in Supplementary information S2 (box)). The largest average annual growth occurred in lower-middle-income (33%) and low-income (21%) regions. Emerging economies among low-middle-income countries (such as Iran, China and Egypt) had the largest country-specific growth; other countries with high growth rates included South Korea, Japan, India, Brazil and Turkey (see Table 6 in Supplementary information S2 (box)). The United States had an average annual growth rate of 2%.
Overall, the data show that the number of registered clinical trials has increased in all geographic regions and development categories in the time period of the study, but growth has been greatest in Asian and Latin American/Caribbean regions, and among low-income and lower-middleincome countries with emerging economies. Given that a substantial proportion of total global biomedical research funding is supplied by either the US government or US-headquartered corporations, these data indicate an outsourcing of clinical research to countries with emerging economies.
Although global health leaders created a roadmap to transform biomedical education to strengthen health systems, there was little mention of improving clinical research capacity (Lancet 376, 1923 (Lancet 376, -1958 2010) . Clinical trials are needed in low-income and middle-income countries to address prevalent conditions and improve clinical research training. However, as research funding expands and more trials are conducted in resource-limited settings, good clinical practices and ethical assurances must be secure. Human participation in clinical research is essential to advancing medicine and public health, and expanding clinical trials requires oversight to ensure research quality and participant protection.
